ATE449097T1 - Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer - Google Patents

Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer

Info

Publication number
ATE449097T1
ATE449097T1 AT06777692T AT06777692T ATE449097T1 AT E449097 T1 ATE449097 T1 AT E449097T1 AT 06777692 T AT06777692 T AT 06777692T AT 06777692 T AT06777692 T AT 06777692T AT E449097 T1 ATE449097 T1 AT E449097T1
Authority
AT
Austria
Prior art keywords
pyridoä2
düpyrimidine
diamine compounds
compounds
ptpib inhibitors
Prior art date
Application number
AT06777692T
Other languages
English (en)
Inventor
Steven Berthel
Adrian Cheung
Kyungjin Kim
Shiming Li
Kshitij Thakkar
Weiya Yun
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE449097T1 publication Critical patent/ATE449097T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AT06777692T 2005-07-21 2006-07-11 Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer ATE449097T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70146705P 2005-07-21 2005-07-21
PCT/EP2006/064091 WO2007009911A1 (en) 2005-07-21 2006-07-11 PYRIDO [2 , 3-D] PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS

Publications (1)

Publication Number Publication Date
ATE449097T1 true ATE449097T1 (de) 2009-12-15

Family

ID=37027932

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06777692T ATE449097T1 (de) 2005-07-21 2006-07-11 Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer

Country Status (14)

Country Link
US (3) US20070021445A1 (de)
EP (1) EP1910359B1 (de)
JP (1) JP4880684B2 (de)
KR (1) KR100962723B1 (de)
CN (1) CN101243081A (de)
AT (1) ATE449097T1 (de)
AU (1) AU2006271809B2 (de)
BR (1) BRPI0613604A2 (de)
CA (1) CA2614443C (de)
DE (1) DE602006010564D1 (de)
ES (1) ES2336603T3 (de)
IL (1) IL188475A0 (de)
MX (1) MX2008000885A (de)
WO (1) WO2007009911A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022078B2 (en) 2004-07-13 2018-07-17 Dexcom, Inc. Analyte sensor
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10320780A1 (de) * 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
DE10352499A1 (de) * 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituierte Dihydrochinazoline II
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
DE102004022672A1 (de) * 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
US7946984B2 (en) 2004-07-13 2011-05-24 Dexcom, Inc. Transcutaneous analyte sensor
WO2006028970A1 (en) 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
US9149266B2 (en) * 2005-05-20 2015-10-06 Neotract, Inc. Deforming anchor device
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
EP2139332A4 (de) * 2007-03-28 2010-04-21 Merck Sharp & Dohme Substituierte pyrido[2,3-d]pyrimidinderivate als cannabinoid-1-rezeptormodulatoren
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (de) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren
JP6899323B2 (ja) 2014-10-14 2021-07-07 ラ ホーヤ インスティテュート オブ アレルギー アンド イミュノロジー 低分子量タンパク質チロシンホスファターゼの阻害剤、及びその使用
CN104744387A (zh) * 2015-03-03 2015-07-01 佛山市赛维斯医药科技有限公司 一类含四氮唑和卤苯结构的ptp1b抑制剂、制备方法及其用途
CN104744386A (zh) * 2015-03-03 2015-07-01 佛山市赛维斯医药科技有限公司 一种含四氮唑结构的ptp1b抑制剂及其用途
CN104803931A (zh) * 2015-03-03 2015-07-29 佛山市赛维斯医药科技有限公司 一类含四氮唑结构的ptp1b抑制剂、制备方法及其用途
CN104803933A (zh) * 2015-03-03 2015-07-29 佛山市赛维斯医药科技有限公司 一种含四氮唑结构的ptp1b抑制剂、其制备方法及用途
CN104803932A (zh) * 2015-03-03 2015-07-29 佛山市赛维斯医药科技有限公司 一类含四氮唑结构的ptp1b抑制剂及其用途
CN104744388A (zh) * 2015-03-03 2015-07-01 佛山市赛维斯医药科技有限公司 含四氮唑结构的ptp1b抑制剂、制备方法及其用途
CN104744385A (zh) * 2015-03-03 2015-07-01 佛山市赛维斯医药科技有限公司 一种含四氮唑结构的ptp1b抑制剂化合物及其用途
CN108530310B (zh) 2017-03-02 2025-01-28 中国科学院上海药物研究所 2-(取代苯杂基)芳香甲酸类fto抑制剂，其制备方法及其应用
US11066420B2 (en) 2017-05-01 2021-07-20 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof
BR112021002207A2 (pt) 2018-08-10 2021-05-04 Diapin Therapeutics, Llc tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios
CN109053771B (zh) * 2018-08-22 2020-02-28 珠海优润医药科技有限公司 一种托法替布的有关物质及其制备方法和应用
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
EP4210833A4 (de) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. Kristalline formen eines kras-g12c-hemmers
EP4216951B1 (de) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Kras-g12d-hemmer
EP4262807A4 (de) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazolin-pan-kras-hemmer
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2207657T3 (es) * 1995-02-27 2004-06-01 F. Hoffmann-La Roche Ag Pirrolderivados de dioxopirrolo.
IL131618A0 (en) * 1997-04-16 2001-01-28 Abbott Lab 5,7-Disubstituted aminopyrido [2,3-D] pyrimidine compounds and their use as adenosine kinase inhibitors
WO2001055147A1 (en) * 2000-01-25 2001-08-02 Warner-Lambert Company PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS
SK11322003A3 (en) * 2001-02-12 2004-10-05 Hoffmann La Roche 6-Substituted pyrido-pyrimidines
EE200400042A (et) * 2001-06-28 2004-10-15 Essential Therapeutics, Inc. 8/17 heterotsüklilised ühendid ning nende kasutamine D-alanüül-D-alaniini ligaasi inhibiitoritena
RS63204A (sr) * 2002-01-17 2006-10-27 Neurogen Corporation Supstituisani analozi hinazolin-4-ilamina kao modulatori kapsaicina
WO2004007468A1 (en) * 2002-07-15 2004-01-22 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
AU2003296984A1 (en) * 2002-12-13 2004-07-09 Neurogen Corporation 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone

Also Published As

Publication number Publication date
US20100280021A1 (en) 2010-11-04
EP1910359B1 (de) 2009-11-18
CA2614443A1 (en) 2007-01-25
AU2006271809B2 (en) 2010-03-18
JP4880684B2 (ja) 2012-02-22
KR20080018957A (ko) 2008-02-28
US20070021445A1 (en) 2007-01-25
KR100962723B1 (ko) 2010-06-09
EP1910359A1 (de) 2008-04-16
WO2007009911A1 (en) 2007-01-25
AU2006271809A1 (en) 2007-01-25
MX2008000885A (es) 2008-03-18
ES2336603T3 (es) 2010-04-14
CA2614443C (en) 2011-03-22
DE602006010564D1 (de) 2009-12-31
CN101243081A (zh) 2008-08-13
JP2009501758A (ja) 2009-01-22
BRPI0613604A2 (pt) 2011-01-18
IL188475A0 (en) 2008-04-13
US20090062276A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
DE602006010564D1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
ATE550037T1 (de) Zusammensetzungen gegen das sars-coronavirus und ihre verwendungen
NO20073790L (no) Kjemiske forbindelser
NO20073788L (no) Kjemiske forbindelser
MY153915A (en) Organic compounds
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
EA201070247A1 (ru) Ингибиторы протеасом
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
NO20076413L (no) Multisykliske forbindelser og fremgangsmater for deres anvendelse
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
CY1116029T1 (el) Σπειροκυκλικες ενωσεις ως αναστολεις αφυδρογονασης τυπου 1 του 11-βητα υδροξυλ στεροειδους
ATE538650T1 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
ATE516286T1 (de) 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes
EA200802213A1 (ru) Способы лечения заболеваний крови
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
MX2009007911A (es) Inhibidores de proteina tirosina fosfatasa 1b aromaticos fusionados.
EA200801997A1 (ru) Новые соединения
WO2009027346A3 (de) 17beta-hydroxysteroid-dehydrogenase-typ1-inhibitoren zur behandlung hormonabhängiger erkrankungen
EA201170795A1 (ru) Антагонисты ccr2 группы 4-азетидинил-1-гетероарил-циклогексанола
EA201170344A1 (ru) Азаиндольные ингибиторы iap
TW200738659A (en) Novel compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1910359

Country of ref document: EP